Bioethics LTD

Bioethics, Ltd. will acquire SILQ Technologies Corporation through a reverse triangular merger, with SILQ becoming a wholly-owned subsidiary.

Bioethics Ltd. and SILQ Technologies have signed a non-binding letter of intent for Bioethics to acquire SILQ in a reverse triangular merger, with SILQ becoming a wholly-owned subsidiary.

Bioethics, Ltd. has appointed Doug Morris to its Board of Directors and as Vice President of Corporate Development, effective April 26, 2024.

Bioethics, Ltd., a shell company, reported a net loss of $128,668 for the nine months ended September 30, 2024, and is pursuing a merger with SILQ Technologies Corporation.

Bioethics, Ltd., a shell company, reported a net loss for the second quarter of 2024 and highlighted its ongoing efforts to secure a business opportunity, including a potential merger with SILQ Technologies Corporation.

Bioethics, Ltd. reported a net loss of $39,653 for the first quarter of 2024, with no revenue and ongoing concerns about its ability to continue as a going concern.

Bioethics, Ltd., a long-standing shell company, reported a significant increase in net losses and a worsening working capital deficit for fiscal year 2024, compounded by the expiration of a key merger agreement.

Bioethics, Ltd., a shell company, reported its 2023 annual results, highlighting its ongoing search for a business acquisition opportunity and its financial position.